Chimeric antigen receptor T cells (CAR-Ts) have shown a remarkable efficacy in hematological malignancies but limited responses in solid tumors. Among solid tumors, CAR-T cell therapy has been particularly explored in brain tumors. CAR-T cells have shown a limited clinical efficacy in various types of brain tumors due to several factors that have hampered their activity, including tumor antigen heterogeneity, the limited access of CAR-T cells to brain tumor cells, limited CAR-T cell trafficking and in vivo persistence and the presence of a highly immunosuppressive tumor microenvironment. Despite these considerations, some recent studies have shown promising antitumor activity of GD2-CAR-T cells on diffuse midline gliomas and neuroblastomas and of CARv3-TEAM-E cells in glioblastomas. However, strategies are required to improve the effect of CAR-T cells in brain tumors, including advanced CAR-T cell design with multiple antigenic targeting and incorporation of combination therapies.
嵌合抗原受体T细胞（CAR-T）在血液系统恶性肿瘤中显示出显著疗效，但在实体瘤中的反应有限。在实体瘤中，CAR-T细胞疗法在脑肿瘤领域得到了特别深入的探索。由于多种因素阻碍了其活性，CAR-T细胞在各类脑肿瘤中的临床疗效有限，这些因素包括肿瘤抗原异质性、CAR-T细胞对脑肿瘤细胞的有限可及性、CAR-T细胞的迁移能力和体内持久性不足，以及高度免疫抑制的肿瘤微环境的存在。尽管存在这些挑战，近期一些研究表明，GD2-CAR-T细胞在弥漫性中线胶质瘤和神经母细胞瘤中，以及CARv3-TEAM-E细胞在胶质母细胞瘤中，均显示出有前景的抗肿瘤活性。然而，仍需采取多种策略以提升CAR-T细胞在脑肿瘤中的疗效，包括采用多抗原靶向的先进CAR-T细胞设计，并结合联合治疗方案。
肿瘤(癌症)患者之家